Spero Therapeutics Inc (SPRO) — Cash Flow Quality Index
Spero Therapeutics Inc (SPRO) has a Cash Flow Quality Index of -0.26x as of December 2025. Operating cash flow of $-8.35 Million is below net income of $31.52 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Spero Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Spero Therapeutics Inc Cash Flow Quality Index (2023–2025)
Historical Cash Flow Quality Index for Spero Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash efficiency ratio of Spero Therapeutics Inc.
Annual Cash Flow Quality Index for Spero Therapeutics Inc (2023–2025)
Year-by-year earnings quality comparison for Spero Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -1.47x | $-12.62 Million | $8.57 Million | ▼ -1.8% |
| 2023 | -1.45x | $-32.99 Million | $22.81 Million | — |